Literature DB >> 22373539

European cancer mortality predictions for the year 2012.

M Malvezzi1, P Bertuccio, F Levi, C La Vecchia, E Negri.   

Abstract

BACKGROUND: Estimating current cancer mortality figures is important for defining priorities for prevention and treatment.
MATERIALS AND METHODS: Using logarithmic Poisson count data joinpoint models on mortality and population data from the World Health Organization database, we estimated numbers of deaths and age-standardized rates in 2012 from all cancers and selected cancer sites for the whole European Union (EU) and its six more populated countries.
RESULTS: Cancer deaths in the EU in 2012 are estimated to be 1,283,101 (717,398 men and 565,703 women) corresponding to standardized overall cancer death rates of 139/100,000 men and 85/100,000 women. The fall from 2007 was 10% in men and 7% in women. In men, declines are predicted for stomach (-20%), leukemias (-11%), lung and prostate (-10%) and colorectal (-7%) cancers, and for stomach (-23%), leukemias (-12%), uterus and colorectum (-11%) and breast (-9%) in women. Almost stable rates are expected for pancreatic cancer (+2-3%) and increases for female lung cancer (+7%). Younger women show the greatest falls in breast cancer mortality rates in the EU (-17%), and declines are expected in all individual countries, except Poland.
CONCLUSION: Apart for lung cancer in women and pancreatic cancer, continuing falls are expected in mortality from major cancers in the EU.

Entities:  

Mesh:

Year:  2012        PMID: 22373539     DOI: 10.1093/annonc/mds024

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  48 in total

Review 1.  Market access of cancer drugs in European countries: improving resource allocation.

Authors:  Kim Pauwels; Isabelle Huys; Minne Casteels; Katelijne De Nys; Steven Simoens
Journal:  Target Oncol       Date:  2013-11-19       Impact factor: 4.493

2.  Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety.

Authors:  Yosuke Inoue; Akio Saiura; Atsushi Oba; Shoji Kawakatsu; Yoshihiro Ono; Takafumi Sato; Yoshihiro Mise; Takeaki Ishizawa; Yu Takahashi; Hiromichi Ito
Journal:  J Gastrointest Surg       Date:  2018-10-10       Impact factor: 3.452

3.  Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development.

Authors:  Jan-Willem van de Loo; Dominika Trzaska; Karim Berkouk; Maria Vidal; Ruxandra Draghia-Akli
Journal:  Oncologist       Date:  2012

4.  Synthesis and antiproliferative and apoptosis-inducing activity of novel 3-substituted-3-hydroxy-2-oxindole compounds.

Authors:  Mona Nazemi Moghaddam; Razieh Jalal; Zohreh Zeraatkar
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-11-09       Impact factor: 2.416

5.  Age-period-cohort effect on female breast cancer mortality in Southern Spain.

Authors:  Ricardo Ocaña-Riola; José María Mayoral-Cortés; Eulalia Navarro-Moreno
Journal:  Med Oncol       Date:  2013-07-25       Impact factor: 3.064

6.  PillCam Colon 2 capsule in patients unable or unwilling to undergo colonoscopy.

Authors:  Lucian Negreanu; Ruxandra Babiuc; Andreea Bengus; Roxana Sadagurschi
Journal:  World J Gastrointest Endosc       Date:  2013-11-16

Review 7.  How to select the optimal treatment for first line metastatic colorectal cancer.

Authors:  Alexander Stein; Carsten Bokemeyer
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

8.  Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation.

Authors:  Linda Heijmen; Edwin E G W Ter Voert; Iris D Nagtegaal; Paul Span; Johan Bussink; Cornelis J A Punt; Johannes H W de Wilt; Fred C G J Sweep; Arend Heerschap; Hanneke W M van Laarhoven
Journal:  Eur Radiol       Date:  2012-09-23       Impact factor: 5.315

Review 9.  Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations.

Authors:  Enikő Orosz; István Ember; Katalin Gombos; László Tóth; Ádám Tarpay; Ákos Pap; Szabolcs Ottó
Journal:  Pathol Oncol Res       Date:  2013-07-19       Impact factor: 3.201

Review 10.  Proteomic biomarkers in lung cancer.

Authors:  M D Pastor; A Nogal; S Molina-Pinelo; A Carnero; L Paz-Ares
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.